Predict your next investment

Immusoft company logo
Corporation
HEALTHCARE | Biotechnology
immusoft.com

See what CB Insights has to offer

Executives

2

Board of Directors

2

Immusoft Board of Directors

2 Board of directors

Immusoft has 2 board of directors, including Julia Moore.

Name

Firm

Work History

Other Seats

Julia Moore

Julia is a Managing Partner at Breakout Ventures, investing at the intersection of technology, biology and chemistry and leveraging the rapid introduction of emerging technologies to effect change in high value markets. Julia has spent her career as an investor and operator, navigating the translation of new technologies in life sciences to customer adoption and scale. She has worked with multiple companies from founding through IPO or M&A and currently serves on the boards of Checkerspot and Immusoft. Julia trained as a research analyst on Wall Street and is also a Kaufman Fellow. She is a graduate of the University of Virginia, where she studied Finance and Bioethics. Associate Director, Stanford University; Director, Business Development & Strategy, TriVascular Inc.; Associate, Investment Team, Kearny Venture Partners; Associate, Equity Research, Thomas Weisel Partners

Checkerspot

Matthew Scholz

Matt is Chief Executive Officer and co-founder of Oisín Bio. A serial entrepreneur with a background in computer security and immunology, Matt is also the founder and CEO of Immusoft, a biotech firm developing a breakthrough technology that will turn a patient's B cells into miniature drug factories. Matthew speaks and presents regularly to university, association and scientific audiences, including those at his alma mater, the University of Washington. He served for several years as a mentor to recipients of the Thiel Fellowship, a program that awarded grants to some of the world’s brightest scientific minds under age 20.

Oisin Biotechnologies

Name

Julia Moore

Matthew Scholz

Firm

Work History

Julia is a Managing Partner at Breakout Ventures, investing at the intersection of technology, biology and chemistry and leveraging the rapid introduction of emerging technologies to effect change in high value markets. Julia has spent her career as an investor and operator, navigating the translation of new technologies in life sciences to customer adoption and scale. She has worked with multiple companies from founding through IPO or M&A and currently serves on the boards of Checkerspot and Immusoft. Julia trained as a research analyst on Wall Street and is also a Kaufman Fellow. She is a graduate of the University of Virginia, where she studied Finance and Bioethics. Associate Director, Stanford University; Director, Business Development & Strategy, TriVascular Inc.; Associate, Investment Team, Kearny Venture Partners; Associate, Equity Research, Thomas Weisel Partners

Matt is Chief Executive Officer and co-founder of Oisín Bio. A serial entrepreneur with a background in computer security and immunology, Matt is also the founder and CEO of Immusoft, a biotech firm developing a breakthrough technology that will turn a patient's B cells into miniature drug factories. Matthew speaks and presents regularly to university, association and scientific audiences, including those at his alma mater, the University of Washington. He served for several years as a mentor to recipients of the Thiel Fellowship, a program that awarded grants to some of the world’s brightest scientific minds under age 20.

Other Seats

Checkerspot

Oisin Biotechnologies

Immusoft Management Team

2 Team Members

Immusoft has 2 executives. Immusoft's founder is Matthew Scholz. Immusoft's former Chief Financial Officer is Eric Garcia.

Name

Work History

Title

Status

Matthew Scholz

Founder

Current

Eric Garcia

Chief Financial Officer

Former

Name

Matthew Scholz

Eric Garcia

Work History

Title

Founder

Chief Financial Officer

Status

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.